7 result(s) for 'Lung'
1 - 7 of 7 results for 'Lung'
Sort by
Show
Translocations of the ALK (anaplastic lymphoma kinase) gene at 2p23 have originally been associated with anaplastic lymphomas, B-cell lymphomas, neuroblastomas and myofibroblastic tumors. At least 21 translocation partners have been described, however 80% of the translocations involves the NPM1 gene (5q35). ALK rearrangements have been described in non-small cell lung cancer (NSCLC) cases. The ALK (2p23) Break probe is optimized to detect translo...
The inversion in 2p21 and 2p23 leading to a fusion of the kinase domain of ALK (anaplastic lymphoma kinase) and EML4 (echinoderm microtubule associated protein like 4) has been described in 5-7% of non-small cell lung cancer (NSCLC) cases. The ALK/EML4 t(2;2); inv(2) Fusion probe is designed as a dual-color assay to detect the fusion of the ALK gene with the EML4 gene by paracentric inversion with breakage and reunion occurring at bands 2p21 and ...
Pericentric inversion of chromosome 10 involving the RET (ret proto-oncogene) gene at chromosome 10q11 is known to increase expression of the RET gene by fusion with KIF5B (10p11). Translocations with other fusion partners have also been described. Elevated expression of RET is observed in non-small cell lung cancer (NSCLC). Translocations involving RET have also been described in thyroid carcinomas. The RET (10q11) Break probe is optimized to de...
Pericentric inversion of chromosome 10 involving the RET (ret proto-oncogene) gene at chromosome 10q11 is known to increase expression of the RET gene by fusion with KIF5B (10p11). Translocations with other fusion partners have also been described. Elevated expression of RET is observed in non-small cell lung cancer (NSCLC), in which the function of tyrosine kinase-based therapeutics is based on the inhibition of such fusion proteins. Translocati...
Translocations of the ALK (anaplastic lymphoma kinase) gene at 2p23 have originally been associated with anaplastic lymphomas, B-cell lymphomas, neuroblastomas and myofibroblastic tumors. At least 21 translocation partners have been described, however 80% of the translocations involves the NPM1 gene (5q35). ALK rearrangements have been described in non-small cell lung cancer (NSCLC) cases. Multiple tyrosine kinsae inhibitors (TKI's) specific for ...
Epidermal growth factor receptor (EGFR) is a cell membrane protein, providing signal transduction and cell growth. It is a member of the Erb-B family of type I receptor tyrosine kinases and implicated in the development and progression of non-small cell lung carcinomas (NSCLC), breast, intestine, and other organs. EGFR has been found to act as a strong prognostic indicator in head and neck, ovarian, cervical, bladder and oesophageal cancers. In t...
The inversion in 2p21 and 2p23 leading to a fusion of the kinase domain of ALK (anaplastic lymphoma kinase) and EML4 (echinoderm microtubule associated protein like 4) has been described in 5-7% of non-small cell lung cancer (NSCLC) cases. Multiple tyrosine kinsae inhibitors (TKI's) specific for ALK have since been approved for first line treatment of NSCLC-patients carrying the fusion gene ALK-EML4. These ALK inhibitors include crizotinib (Xalko...